New Findings: Retrospective Cohort Study: Common hypertension drugs may reduce the risk of colorectal cancer.

Introduction: colorectal cancer is one of the most common gastrointestinal malignancies, which can recur and metastasize.has increased significantly in recent years, and the incidence rate of incidence rate is higher in the 41~65 year old population.colorectal cancer has no obvious symptoms at the initial stage, and the development process is relatively slow.once developed to the middle and late stage, it will cause serious threat to life.drugs commonly used to treat hypertension also reduce the risk of colorectal cancer in patients, according to a new study published on July 5 in the American Heart Association Journal hypertension.angiotensin converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB) are used to treat diseases such as heart failure, hypertension or heart disease.these drugs inhibit or block angiotensin, a chemical that causes arterial stenosis.doctors usually prescribe these drugs to relax and relax blood vessels in patients with hypertension, thereby lowering blood pressure.according to the findings of this large study, taking these drugs may also reduce the risk of colorectal cancer.colorectal cancer is the third most common cancer and the second leading cause of cancer death in the world.Dr. Wai K. Leung, a clinical professor at the University of Hong Kong, China, said, "the role of ACE inhibitors and ARBs in the development of cancer is controversial, and in some cases, the results are contradictory.the results of previous studies were limited by several factors, including the small number of patients and the data only in short-term follow-up.our results provide new insights into the potential role of these drugs in the prevention of colorectal cancer.this is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on the development of colorectal cancer, and it is also based on a large number of patients without colorectal cancer at the beginning of the study."this is a Hong Kong wide retrospective cohort study. The health records of 187897 adult patients (40 years and older) in Hong Kong from 2005 to 2013 were reviewed. All of these patients had negative colonoscopy at baseline.exclusion criteria included colorectal cancer less than 6 months found by colonoscopy, previous colorectal cancer, inflammatory bowel disease, and colectomy.the main outcome was a diagnosis of colorectal cancer 6 to 36 months after colonoscopy. colorectal cancer can be divided into proximal (proximal splenic curvature) and distal cancer. propensity score regression adjustment was performed on 23 covariates (including patient factors, concurrent medication and endoscopic center performance) with angiotensin converting enzyme inhibitor / angiotensin receptor blocker (used within 5 years before colonoscopy ≥ 180 days), and the adjusted risk ratio of colorectal cancer was obtained. of the 187897 eligible patients, 30856 (16.4%) were users of ACE inhibitors / angiotensin receptor blockers. 854 cases (0.45%) developed colorectal cancer within 6 months to 36 months after index colonoscopy [proximal cancer: 147 cases (17.2%)]. these drugs were associated with a lower risk of colorectal cancer less than 3 years after index colonoscopy, but not with colorectal cancer risk greater than 3 years; for each year of increased drug use, the adjusted risk ratio decreased by 5%. angiotensin converting enzyme inhibitors / angiotensin receptor blockers are associated with a lower risk of colorectal cancer. the analysis found that: · those who took hypertension drugs such as ACE-I or ARBs had a 22% lower risk of colorectal cancer in the next three years; · the benefits of ACE-I and ARBs were seen in patients aged 55 or older and patients with a history of colon polyps; · drug related benefits were limited to the first three years after negative baseline colonoscopy. Leung said, "although ACE-I and ARBs are used in patients with hypertension, heart failure and kidney disease, reducing the risk of colorectal cancer may be another factor for doctors to consider when choosing antihypertensive drugs. "this is a retrospective study to review whether patients taking these drugs develop colorectal cancer. the researchers pointed out that the results of the study should be validated by prospective randomized controlled studies, which will actively track patients to determine the potential benefits of these drugs for colorectal cancer risk. Ref: [1] [2] recommended reading: fighting the epidemic situation, translational medicine network content team series report: [new discovery] the latest research of the Chinese University of Hong Kong: abnormal protein in the intestine can cause Alzheimer's disease [Nature] Austrian scientists: how does the immune system produce a large number of antibodies? [new discovery] US scientists discover the key to cancer -- specific sites of DNA methylation imbalance